Advisor Group Holdings, Inc. Morphic Holding, Inc. Transaction History

Advisor Group Holdings, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$26.12 - $34.07 $365 - $476	14 Added 7.0%	214 $7,000
Q1 2024 May 10, 2024	SELL	$26.64 - $40.31 $16,729 - $25,314	-628 Reduced 75.85%	200 $7,000
Q4 2023 Feb 12, 2024	SELL	$19.95 - $31.0 $239 - $372	-12 Reduced 1.43%	828 $23,000
Q3 2023 Nov 13, 2023	SELL	$21.33 - $59.42 $107,737 - $300,130	-5,051 Reduced 85.74%	840 $19,000
Q2 2023 Aug 10, 2023	BUY	$34.33 - $62.11 $176,421 - $319,183	5,139 Added 683.38%	5,891 $337,000
Q1 2023 May 12, 2023	SELL	$26.01 - $48.69 $5,149 - $9,640	-198 Reduced 20.84%	752 $28,000
Q4 2022 Feb 10, 2023	BUY	$24.14 - $30.37 $22,933 - $28,851	950 New	950 $25,000
Q1 2022 May 04, 2022	SELL	$36.25 - $52.02 $22,910 - $32,876	-632 Closed	0 $0
Q3 2021 Nov 05, 2021	SELL	$53.61 - $67.5 $19,728 - $24,840	-368 Reduced 36.8%	632 $36,000
Q2 2021 Aug 02, 2021	BUY	$45.13 - $64.99 $45,130 - $64,989	1,000 New	1,000 $57,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.